Skip to main content

AI assistant

Sign in to chat with this filing

The assistant answers questions, extracts KPIs, and summarises risk factors directly from the filing text.

Sanofi Capital/Financing Update 2017

Sep 7, 2017

1643_iss_2017-09-07_b76f3e58-cdcd-4b2a-bc0f-a9db7d90df93.pdf

Capital/Financing Update

Open in viewer

Opens in your device viewer

Sanofi rated AA by Scope Ratings

Paris, France - September 7, 2017 - Sanofi announced today that the European ratings agency Scope Ratings AG ("Scope") assigned the company a AA long term rating and a S-1+ short-term rating. The outlook is stable.

These ratings confirm Sanofi's high credit quality and provide investors with an increased diversity of independent opinions.

Scope is accredited and regulated by the European Securities and Markets Authority. It is the third credit rating agency to rate Sanofi, as the company is already rated AA by Standard & Poor's and A1 by Moody's. Both ratings have stable outlooks.

About Sanofi

Sanofi, a global healthcare leader, discovers, develops and distributes therapeutic solutions focused on patients' needs. Sanofi is organized into five global business units: Diabetes and Cardiovascular, General Medicines and Emerging Markets, Sanofi Genzyme, Sanofi Pasteur and Consumer Healthcare. Sanofi is listed in Paris (EURONEXT: SAN) and in New York (NYSE: SNY).

Contacts:

Media Relations Laurence Bollack Tel. : +33 (0)1 53 77 46 46 [email protected]

Investor Relations George Grofik Tel.: +33 (0)1 53 77 45 45 [email protected]